Pain Volatility and Prescription Opioid Addiction Treatment Outcomes in Patients with Chronic Pain

Overview

Journal Exp Clin Psychopharmacol

Publisher American Psychological Association

Specialty Pharmacology

Date 2015 Aug 25

PMID 26302337

Citations 23

Authors

Matthew J Worley

Keith G Heinzerling

Steven Shoptaw

Walter Ling

Affiliations

Soon will be listed here.

Abstract

The combination of prescription opioid dependence and chronic pain is increasingly prevalent and hazardous to public health. Variability in pain may explain poor prescription opioid addiction treatment outcomes in persons with chronic pain. This study examined pain trajectories and pain volatility in patients with chronic pain receiving treatment for prescription opioid addiction. We conducted secondary analyses of adults with chronic pain (n = 149) who received buprenorphine/naloxone (BUP/NLX) and counseling for 12 weeks in an outpatient, multisite clinical trial. Good treatment outcome was defined as urine-verified abstinence from opioids at treatment endpoint (Week 12) and during at least 2 of the previous 3 weeks. Pain severity significantly declined over time during treatment (b = -0.36, p < .001). Patients with greater pain volatility were less likely to have a good treatment outcome (odds ratio = 0.55, p < .05), controlling for baseline pain severity and rate of change in pain over time. A 1 standard deviation increase in pain volatility was associated with a 44% reduction in the probability of endpoint abstinence. The significant reduction in subjective pain during treatment provides observational support for the analgesic effects of BUP/NLX in patients with chronic pain and opioid dependence. Patients with greater volatility in subjective pain during treatment have increased risk of returning to opioid use by the conclusion of an intensive treatment with BUP/NLX and counseling. Future research should examine underlying mechanisms of pain volatility and identify related therapeutic targets to optimize interventions for prescription opioid addiction and co-occurring chronic pain.

Citing Articles

Electroacupuncture produces analgesic effects via cannabinoid CB1 receptor-mediated GABAergic neuronal inhibition in the rostral ventromedial medulla.

Wan K, Xu Q, Shi Y, Cui C, Lei J, Zhang K Chin Med. 2025; 20(1):30.

PMID: 40038719 PMC: 11881457. DOI: 10.1186/s13020-025-01083-4.

Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial.

Salay M, Edwards K, Winstanley E, Bachrach R, Bulls H, Hanmer J Subst Use Addctn J. 2024; 46(1):201-207.

PMID: 38907678 PMC: 11863306. DOI: 10.1177/29767342241261562.

Trauma exposure across the lifespan among individuals engaged in treatment with medication for opioid use disorder: differences by gender, PTSD status, and chronic pain.

Rodriguez M, Colgan D, Leyde S, Pike K, Merrill J, Price C Subst Abuse Treat Prev Policy. 2024; 19(1):25.

PMID: 38702783 PMC: 11067259. DOI: 10.1186/s13011-024-00608-8.

Mental Health Distress Is Associated With Higher Pain Interference in Patients With Opioid Use Disorder Stabilized on Buprenorphine or Methadone.

Leyde S, Price C, Colgan D, Pike K, Tsui J, Merrill J Subst Use Addctn J. 2024; 45(3):423-433.

PMID: 38327009 PMC: 11221630. DOI: 10.1177/29767342241227402.

Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data.

John W, Mannelli P, Hoyle R, Greenblatt L, Wu L Drug Alcohol Depend Rep. 2023; 3:100048.

PMID: 36845986 PMC: 9948869. DOI: 10.1016/j.dadr.2022.100048.

References

Chen K, Chen L, Mao J . Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014; 120(5):1262-74. PMC: 3999180. DOI: 10.1097/ALN.0000000000000170. View

Ballantyne J, LaForge S . Opioid dependence and addiction during opioid treatment of chronic pain. Pain. 2007; 129(3):235-255. DOI: 10.1016/j.pain.2007.03.028. View

Sullivan M, Howe C . Opioid therapy for chronic pain in the United States: promises and perils. Pain. 2013; 154 Suppl 1:S94-S100. PMC: 4204477. DOI: 10.1016/j.pain.2013.09.009. View

Dreifuss J, Griffin M, Frost K, Fitzmaurice G, Potter J, Fiellin D . Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend. 2013; 131(1-2):112-8. PMC: 3638044. DOI: 10.1016/j.drugalcdep.2012.12.010. View

Larson M, Paasche-Orlow M, Cheng D, Lloyd-Travaglini C, Saitz R, Samet J . Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction. 2007; 102(5):752-60. DOI: 10.1111/j.1360-0443.2007.01759.x. View

Cofta-Woerpel L, McClure J, Li Y, Urbauer D, Cinciripini P, Wetter D . Early cessation success or failure among women attempting to quit smoking: trajectories and volatility of urge and negative mood during the first postcessation week. J Abnorm Psychol. 2011; 120(3):596-606. PMC: 3153568. DOI: 10.1037/a0023755. View

Compton W, Volkow N . Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2005; 81(2):103-7. DOI: 10.1016/j.drugalcdep.2005.05.009. View

Cook D, Stegner A, Ellingson L . Exercise alters pain sensitivity in Gulf War veterans with chronic musculoskeletal pain. J Pain. 2010; 11(8):764-72. DOI: 10.1016/j.jpain.2009.11.010. View

Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y . Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci. 1995; 56(15):PL285-90. DOI: 10.1016/0024-3205(95)00078-x. View

10.

Ehde D, Dillworth T, Turner J . Cognitive-behavioral therapy for individuals with chronic pain: efficacy, innovations, and directions for research. Am Psychol. 2014; 69(2):153-66. DOI: 10.1037/a0035747. View

11.

Ling W, Mooney L, Hillhouse M . Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev. 2011; 30(3):300-5. PMC: 4170948. DOI: 10.1111/j.1465-3362.2010.00271.x. View

12.

Bushnell M, ceko M, Low L . Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci. 2013; 14(7):502-11. PMC: 4465351. DOI: 10.1038/nrn3516. View

13.

Keller S, Bann C, Dodd S, Schein J, Mendoza T, Cleeland C . Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004; 20(5):309-18. DOI: 10.1097/00002508-200409000-00005. View

14.

Cacciola J, Alterman A, McLellan A, Lin Y, Lynch K . Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend. 2006; 87(2-3):297-302. DOI: 10.1016/j.drugalcdep.2006.09.002. View

15.

Kwon J, Chang I . Pain, catastrophizing, and depression in chronic prostatitis/chronic pelvic pain syndrome. Int Neurourol J. 2013; 17(2):48-58. PMC: 3713242. DOI: 10.5213/inj.2013.17.2.48. View

16.

Campbell N, Lovell A . The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci. 2012; 1248:124-39. DOI: 10.1111/j.1749-6632.2011.06352.x. View

17.

Windmill J, Fisher E, Eccleston C, Derry S, Stannard C, Knaggs R . Interventions for the reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev. 2013; (9):CD010323. DOI: 10.1002/14651858.CD010323.pub2. View

18.

Atluri S, Sudarshan G, Manchikanti L . Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014; 17(2):E119-28. View

19.

Ren Z, Shi J, Epstein D, Wang J, Lu L . Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving. Psychopharmacology (Berl). 2009; 204(3):423-9. PMC: 3697848. DOI: 10.1007/s00213-009-1472-0. View

20.

Webster L . Breakthrough pain in the management of chronic persistent pain syndromes. Am J Manag Care. 2008; 14(5 Suppl 1):S116-22. View